Prospettive Sociali e Sanitarie

Matcheri S. Keshavan, Harpreet S. Duggal, Gautami Veeragandham, Nancy M. McLaughlin, Debra M. Montrose,
Gretchen L. Haas, and Nina R. Schooler
Personality Dimensions in First-Episode Psychoses 102-109
Philip D. Harvey, Barton W. Palmer, Robert K. Heaton, Somaia Mohamed, John Kennedy, and Adam Brickman
Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study 110-117
Karen A. Graham, Diana O. Perkins, Lloyd J. Edwards, Robert C. Barrier, Jr., Jeffrey A. Lieberman, and Joyce B. Harp
Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis 118-123
Robert W. Buchanan, M. Patricia Ball, Elaine Weiner, Brian Kirkpatrick, James M. Gold, Robert P. McMahon, and
William T. Carpenter, Jr.
Olanzapine Treatment of Residual Positive and Negative Symptoms 124-129
Richard C. Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood Dadvand, Wynn Wynn Paing, and Rita A.
Shaughnessy
Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-
Controlled Trial 130-136
Eric Hollander, Stefano Pallanti, Andrea Allen, Erica Sood, and Nicolo Baldini Rossi
Does Sustained-Release Lithium Reduce Impulsive Gambling and Affective Instability Versus Placebo in Pathological
Gamblers With Bipolar Spectrum Disorders? 137-145
Eric J. Lenze, Benoit H. Mulsant, M. Katherine Shear, Mary Amanda Dew, Mark D. Miller, Bruce G. Pollock, Patricia
Houck, Barbara Tracey, and Charles F. Reynolds, III
Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week
Randomized, Placebo-Controlled Trial 146-150
Edna B. Foa, Michael R. Liebowitz, Michael J. Kozak, Sharon Davies, Rafael Campeas, Martin E. Franklin, Jonathan
D. Huppert, Kevin Kjernisted, Vivienne Rowan, Andrew B. Schmidt, H. Blair Simpson, and Xin Tu
Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in
the Treatment of Obsessive-Compulsive Disorder 151-161
Martina Hummer, Peter Malik, Rudolf W. Gasser, Alex Hofer, Georg Kemmler, Roy Cesar Moncayo Naveda, Maria
A. Rettenbacher, and W. Wolfgang Fleischhacker
Osteoporosis in Patients With Schizophrenia 162-167
Kai G. Kahl, Sebastian Rudolf, Beate M. Stoeckelhuber, Leif Dibbelt, Hans-Björn Gehl, Kerstin Markhof, Fritz
Hohagen, and Ulrich Schweiger
Bone Mineral Density, Markers of Bone Turnover, and Cytokines in Young Women With Borderline Personality
Disorder With and Without Comorbid Major Depressive Disorder 168-174
Brief Reports:
Alan J. Thomas, Sue Davis, Christopher Morris, Elizabeth Jackson, Richard Harrison, and John T. O’Brien
Increase in Interleukin-1ß in Late-Life Depression 175-177
Max L. Stek, David J. Vinkers, Jacobijn Gussekloo, Aartjan T.F. Beekman, Roos C. van der Mast, and Rudi G.J.
Westendorp
Is Depression in Old Age Fatal Only When People Feel Lonely? 178-180
Kathryn L. Bleiberg and John C. Markowitz
A Pilot Study of Interpersonal Psychotherapy for Posttraumatic Stress Disorder 181-183
Jo Anne Sirey, Martha L. Bruce, and George S. Alexopoulos
The Treatment Initiation Program: An Intervention to Improve Depression Outcomes in Older Adults 184-186
Donna A. Wirshing, Mark J. Sergi, and Jim Mintz
A Videotape Intervention to Enhance the Informed Consent Process for Medical and Psychiatric Treatment Research
186-188
Margaret Maglione, Karen Miotto, Martin Iguchi, Lara Jungvig, Sally C. Morton, and Paul G. Shekelle
Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events 189-191